English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

While pharmacological methods are the mainstay for transplant immunosuppression, cellbased therapies are being increasingly studied as a potential alternative. Currently available immunosuppressive medications lack specificity leaving transplant recipients vulnerable to infection, malignancy, and drug related toxicities while still being susceptible to chronic rejection. Donor-specific tolerance would be clearly superior to global immunosuppression yet remains an elusive goal. Recent advances in cell-based therapies along with an improved understanding of central and peripheral tolerance mechanisms offer new possibilities for donor-specific immunomodulation. Amongst the many types of cell-based therapies tested to date some of the most successful thus far have involved donor stem cell transplantation in living-donor kidney transplant recipients1. However, the need ex vivo cell manipulation along with T cell depletion and bone marrow conditioning makes these methods arduous for many transplant recipients, and impractical for those receiving deceased donor organs. As an alternative cellular therapy, dendritic cells (DCs) are particularly attractive because of their role as central regulators of immune responses2.

Dendritic Cell Therapy in Transplantation, Phenotype Governs Destination and Function